Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA Bilthoven, Netherlands.
Sci Transl Med. 2023 Feb 22;15(684):eabn4338. doi: 10.1126/scitranslmed.abn4338.
The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.
我们尚不清楚严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)变体引起关注(VOCs)在多大程度上突破感染或疫苗诱导的免疫。我们分析了 2021 年 3 月至 8 月期间,通过荷兰全国社区检测获得的已知免疫状态个体的 28578 个测序 SARS-CoV-2 样本。我们发现,与 Alpha(B.1.1.7)变体相比,Beta(B.1.351)、Gamma(P.1)或 Delta(B.1.617.2)变体在接种疫苗后感染的风险增加。不同疫苗之间未发现明显差异。然而,在完全接种疫苗后 14 至 59 天内,与≥60 天后相比,效果更大。与疫苗诱导的免疫相比,在具有感染诱导的免疫的个体中,Beta、Gamma 或 Delta 变体相对于 Alpha 变体没有增加再感染的风险。